The last 5 years of technological advances with major impact on clinical magnetic resonance (MR) are discussed, with greater emphasis on those that are most recent. These developments have already had a critical positive effect on clinical diagnosis and therapy and presage continued rapid improvements for the next 5 years. This review begins with a discussion of 2 topics that encompass the breadth of MR, in terms of anatomic applications, contrast media, and MR angiography. Subsequently, innovations are discussed by anatomic category, picking the areas with the greatest development, starting with the brain, moving forward to the liver and kidney, and concluding with the musculoskeletal system, breast, and prostate. Two final topics are then considered, which will likely, with time, become independent major fields in their own right, interventional MR and MR positron emission tomography (PET).
T his review draws primarily upon research published in Investigative Radiology during the past 5 years, with reference, on occasion, to relevant work published elsewhere in the literature. Hot topics are emphasized by reference to abstracts presented at the most recent International Society for Magnetic Resonance in Medicine meeting, held in late April 2013 in Salt Lake City, UT. Focusing on the topics most widely applicable today and in the immediate future for departments of diagnostic radiology worldwide, research involving the heart and studies conducted at 7 T were intentionally excluded.
Contrast Media
The injection of intravenous contrast media, specifically the use of gadolinium chelates, is an integral part of clinical magnetic resonance (MR) today. Almost half of administered doses are for the evaluation of central nervous system disease, with additional major areas being contrast-enhanced MR angiography (CE-MRA), liver imaging, and breast evaluation for malignancy.
Targeted MR contrast agents are in their infancy. Seminal work in the last 5 years examined a peptide targeted to fibrin 1,2 and a peptide-targeted nanoglobular agent. 3 Important research has also been published regarding our understanding of relaxivity, providing a path for incremental improvements in relaxivity of current gadoliniumbased agents. 4, 5 Nanotechnology and other approaches have the potential to provide an improvement in relaxivity for MR agents on the order of 1000-fold, when compared with current agents. 6 Our understanding of chemistry and structures has advanced to the extent that the development of such agents is possible. This would enable targeted applications analogous to radioactive tracers, the use of much higher doses than that in practice today for the gadolinium chelates (90.1 mmol/kg), and a marked improvement in the safety profile of gadolinium chelates overall, with routine use allowing markedly lower doses of gadolinium ion to be administered. Multimodal agents 7 and theragnostic agents 8 (agents with combined diagnostic and therapeutic use) are also in development, with the latter, in particular, a major current area of investigation, and likely to remain so for the next decade. Chelate stability, high-dose administration, and gadolinium ion retained in the body have become areas of great concern in recent years, given the advent of nephrogenic systemic fibrosis. 9, 10 This disease, discovered and linked to the administration of the less-stable gadolinium chelates in patients with renal dysfunction, continues
Magnetic Resonance Angiography
Significant advances are continuing to be made in MRA, for techniques both with and without intravenous contrast use. The advent of nephrogenic systemic fibrosis spurred research in noncontrast MRA, with these techniques robust in widespread applications today, 12Y15 although, in general, more time-consuming and of lower diagnostic quality when compared with contrast-enhanced techniques. Low-dose contrast-enhanced techniques have similarly gained interest. 16 The development of imaging techniques allowing image acquisition during continuous table motion was critical to the development of MR positron emission tomography (PET), discussed in depth later, with the development of continuously moving table CE-MRA thus also enabled. 17 Flow-sensitive 4-dimensional phase contrast is an important innovation, revealing altered flow patterns that may be missed by traditional analysis. 18 Time-resolved techniques were first introduced more than 10 years ago and provide, in current advanced implementations, critical diagnostic information otherwise not available. 19, 20 These techniques are likely among the first to benefit from the developments in compressed sensing in the future. Preliminary work has already been shown with techniques that can acquire greater than 10-foldYaccelerated dynamic CE-MRA volumes with similar spatial resolution to that of current breath-hold techniques. 21 Compressed sensing holds great promise for improving both temporal and spatial resolution in CE-MRA.
Brain
Brain MR imaging is often considered to be technologically mature; however, in fact, this area, like all anatomic areas in MR, is seeing substantial improvements and will continue to so evolve over the next decade. Diffusion-weighted imaging was first introduced for the visualization of cytotoxic edema (in early brain ischemia) and was thought, for many years, to be of little other utility. Like all MR parameters, diffusion lends itself to evaluation of many anatomic regions and disease processes, only that it was limited in early application because of problems with image acquisition. Bulk susceptibility artifacts, due to the use of single-shot echo planar technique, represented the major impediment to greater use across anatomic areas and, indeed, improved brain imaging. Multiple techniques have been developed in recent years to limit bulk susceptibility effects, 22Y24 with the most important being the introduction of a readout-segmented echoplanar imaging (rs-EPI) technique. 25 The result, clinically, is a vast improvement in image quality, reducing substantially bulk susceptibility artifacts along with image blur. This approach can be extended through simultaneous multislice acquisition and further through 3-dimensional (3D) multislab acquisition. 26 Although the current 3D acquisition requires an 11-minute scan, the spatial resolution is 1.5-mm isotropic, with several viable approaches for a reduction in scan time while maintaining the requisite signal-to-noise ratio (SNR). The recent introduction of a 64-channel head-neck array coil at 3 T further extends this approach, making possible simultaneous diffusion-weighted MR of the brain and cervical spinal cord. 27 Although clinical imaging is already currently being performed in areas outside the brain, for example, the globes (and, indeed, in general body imaging; eg, MR-PET covered later in this article), 28 with nonsegmented single shot EPI diffusion-weighted imaging (DWI), the availability of these new techniques, and in particular rs-EPI, will further improve clinical image quality and utility.
It is commonly assumed in clinical practice that all brain metastases are visualized after intravenous contrast administration. Substantial indirect evidence exists in the published literature that this conclusion is false, specifically studies showing additional metastases with high-dose contrast administration (0.3 mmol/kg of gadolinium chelate), and improved visualization of contrast enhancement with isotropic, high-resolution 3D imaging and at 3 T (as compared with 1.5 T). A basic research publication in 2011, evaluating brain metastases from breast cancer in a mouse model, established that metastases, in particular smaller lesions, may not manifest permeability of the blood-brain barrier. 29 In 2013, another investigation emphasized the point that technique is critical for the identification of abnormal contrast enhancement and, thus, smaller brain metastases in clinical practice (Fig. 1) . Specifically, 3D MP-RAGE (magnetization-prepared rapid gradient echo, a gradient echoYbased technique), which is commonly used in clinical practice after contrast, was shown to be inferior for lesion detection as compared with 3D SPACE (sampling perfection with application optimized contrasts by using different flip angle evolutions, a spin echoYbased technique), with the 2 scans compared for identical acquisition time and voxel size. 30 Three articles published in 2012 to 2013 emphasized new scan approaches for brain imaging, providing either additional information in specific disease entities or information not previously available by MR. A 3D T1-weighted double inversion magnetizationprepared rapid gradient echo sequence (MP2RAGE) was applied in patients with multiple sclerosis (MS) and determined to outperform MP-RAGE for lesion contrast-to-noise ratio, count, and volume assessment. 31 This approach also provides quantitative T1-relaxation time maps, allowing better discrimination of lesion subtypes and staging of lesion activity. A 3D T1-weighted dynamic contrast-enhanced MR (DCE-MR) imaging acquisition, with high spatial and temporal resolution, was developed and combined with 2-compartment modeling for the quantification of cerebral blood flow, cerebral blood volume, FIGURE 1. Improved MR imaging technique for visualization of abnormal contrast enhancement and, thus, identification of small brain metastases. SPACE, a fast spin echoYbased high-resolution 3D technique, offers in its current implementation greater sensitivity to lesion enhancement, as illustrated on the left-hand image for a lesion involving the anterior low frontal lobe (arrow). This metastasis was not visualized on the equivalent MP-RAGE acquisition, presented on the right, a gradient echoYbased technique. Adapted from Reichert et al.
and permeability surface area product. 32 This was applied in patients with MS for quantitative assessment, without prior knowledge of anatomic location, of both MS lesions and normal-appearing white matter. And equally innovative and potentially important, a cardiac-gated phase contrast technique was optimized and used to estimate intracranial pressure in children with shunt-treated hydrocephalus. This approach was validated and provides a promising tool for quantifying intracranial pressure through MR, with anticipation of an important role in patients with suspected shunt malfunction. 33 
Liver
In recent years, techniques have been developed to quantitate intrahepatic lipid (IHL) through MR rapidly, accurately, and with relative ease, which are now available clinically. 34 Such information is of increasing value in the modern world, because of obesity, with IHL known to provide a better measure of obesity than previously used measures such as body mass index or skinfold thickness. The assessment of IHL assumes an increasing importance for the evaluation of patients with obesity, with elevated IHL an important precursor for the development of insulin resistance and type 2 diabetes. The techniques available today in MR, for the assessment of IHL, provide accurate measurements and are not confounded by the presence of liver iron, inflammation, or fibrosis/cirrhosis.
35Y37
The field of MR is also on the verge of substantial improvements in 3D liver imaging, based, in part, on new developments in parallel imaging and echo sharing. For the past decade, parallel imaging has largely relied upon the acquisition technique generalized autocalibrating partially parallel acquisition (GRAPPA). A new parallel acquisition technique, controlled aliasing in parallel imaging results in higher acceleration (CAIPIRINHA), has recently been introduced and provides significantly higher image quality, with less parallel imaging artifacts and superior SNR. What, in the past, has routinely been a 20-second acquisition (conventional breath-hold liver imaging) may indeed, in the near future, be replaced by a 10-second acquisition, with many other variants possible because of the improved parallel imaging performance in combination with higher SNR. 38 Combining CAIPIRINHA with view sharing and Dixon water-fat separation leads to a robust new approach for dynamic imaging of the upper abdomen, which provides both high temporal and spatial resolution. 39 This approach yields reliable dynamic information, not subject to contrast bolus timing issues, with improved lesion detectability (eg, in the arterial phase) and visualization of contrast kinetics (with calculation of quantitative perfusion measures) for focal lesions. Such techniques may also prove useful for imaging of the breast, pelvis, and extremities. Another direction of development concerns solutions for liver perfusion imaging, similarly requiring high temporal and spatial resolution, but with the need to be acquired during free breathing and without view sharing, for high data fidelity. 40 
Kidney
In the last 5 years, blood oxygen levelYdependent (BOLD) MR measurements of the renal cortex and medulla have been investigated in regard to providing a measurement of tissue oxygenation applicable to human disease. 3 T, when compared with 1.5 T, more effectively detects developing parenchymal injury related to impaired oxygenation. 41 On the basis of animal studies, BOLD MR may prove useful in diabetes, in which hypoxia is thought to be an important factor, evaluating renal oxygenation and monitoring therapeutic intervention based on improving tissue hypoxia and preventing progression of renal disease. 42 Recent investigation has focused on improving the analysis of renal BOLD data, proposing an approach that is less labor-intensive and less prone to errors. 43 Prospective navigation has also been recently demonstrated with BOLD, allowing longer imaging times and an unprecedented improvement in spatial resolution and SNR, furthering the potential of this technique for the assessment of chronic kidney disease. 44 Other MR techniques are being developed as well for the evaluation of renal function. This includes the use of low-dose DCE-MR to assess glomerular filtration rate. A recent study has shown that this approach is suitable to evaluate functional loss in partial nephrectomies and compensatory increase in renal function in the contralateral kidney. 45 
Musculoskeletal System
Imaging of the musculoskeletal system is being advanced by both the introduction of improved scan sequences (predominantly 3D acquisitions) 46 together with a renewed emphasis on the development of scan techniques that reduce metal artifacts. 47, 48 Substantial progress has already been achieved to date in terms of the development and clinical introduction of metal artifact reduction techniques (Fig. 2) , which are critical for imaging of the postoperative patient, for detection of infection, prosthesis loosening, and periprosthetic bony fractures. A major limitation, however, to novel techniques for reducing metal artifact, such as slice encoding for metal artifact correction (SEMAC), is scan time. SEMAC is a good candidate for acceleration using compressed sensing in part because the additional dimension acquired is inherently sparse. This approach was recently shown to allow image acquisition for the knee, with an orthopedic prosthesis in place, in a clinically acceptable scan time of 5 minutes. 49 
Breast
Breast MR imaging continues to make strides in terms of improved lesion detection and diagnosis. 3 T, when compared with 1.5 T, offers improved spatial resolution and also temporal resolution for dynamic studies. 50 In the United States, 3 T imaging of the breast has largely replaced 1.5 T, in centers where state-of-the-art scanners with both field strengths are available. Dense breasts represent a challenge for mammography, and MR in this population should be considered for routine evaluation. When compared with mammography and ultrasound, MR detected more malignant lesions and led to fewer misdiagnoses in this population. 51 In a multicenter Italian study published in 2011, MR was shown to outperform both mammography and ultrasonography, whether used separately or in combination, for screening women at high risk for breast cancer, whether younger or older than 50 years. 52 Breast MR is so impressive in terms of lesion visualization that, on the basis of a 2012 study, it is recommended for all patients with known breast cancer for staging and surgical planning, positively affecting patient management with the recurrence rate at long-term follow-up low. 53 Current investigation in the breast has focused on the value of DWI 54 and DCE-MR, 55 with elevation of parameters from the latter associated with shorter survival and providing superior prognostic information to traditional clinical indicators. 56 
Prostate
Prostate MR continues to be an active area of research, with increasing clinical applicability. By 2009, the value of apparent diffusion coefficient (ADC) and, to a lesser extent, that of quantitative T2 measurement were evident for assessing cell density in the prostate, suggesting the utility of these parameters for assessing tumor aggressiveness. 57 Research published in 2010 extended the utility of ADC values to pelvic lymph nodes in prostate carcinoma, suggesting improved ability to discriminate between benign and malignant nodes when compared with size criteria. 58 Dynamic contrast-enhanced MR 59 and proton spectroscopy were evaluated and determined to be of value soon thereafter in discriminating cancer from benign tissue, 60 leading to a publication in 2012 comparing the relative value of the different MR parameters available (T2, DWI, DCE-MR, and proton spectroscopy). All parameters were shown to be of value in separating cancer from noncancer areas, in the peripheral zone of the prostate, with ADC as the best single parameter. Proving the diagnostic accuracy of multiparametric MR imaging at 3 T and determination of the FIGURE 3. A cancer-suspicious region in the left peripheral zone of the prostate is identified on T2-weighted (A), dynamic contrast-enhanced (B), and diffusion-weighted (C) MR images at 3 T in a 62-year-old man. The lesion demonstrates discrete hypointensity in A, hyperperfusion on the dynamic contrast-enhanced scan, and hypointensity on DWI (with hypointensity on the ADC map, not shown). In patients eligible for active surveillance, DWI shows promise for risk stratification, identifying and targeting prostate carcinoma for biopsy, assisting in determining Gleason grade, and preventing undergrading. Adapted from Somford et al. 64 parameters contributing most to prostate cancer detection and localization is the focus of an ongoing multicenter study. 61 Recent clinical studies have focused on diffusion-weighted MR, highlighting its importance for predicting the presence of high-grade tumor and clarifying its role (Fig. 3) . 62Y65 Computation of DWI with higher b values than those typically acquired, due to time and SNR constraints, offers an additional refinement of clinical technique. 66 
Interventional MR
Five to 10 years ago, magnet technology was sufficient to support development of the field of interventional MR, in particular with the introduction of the initial generation of short, wide-bore 1.5-T systems. However, the development of the hardware needed in the MR environment was not sufficiently mature at that time, with substantial problems still to be overcome because of the main magnetic field, the gradients, and radiofrequency excitation. In 2009, a total of 2 articles describing the first truly MR-compatible guidewires were published. Both used passive marking concepts and demonstrated good visibility, with handling characteristics (stiffness, flexibility, steerability, and pushability) comparable with current guidewires in x-rayYbased angiography. 67, 68 Feasibility studies appeared as early as 2003 regarding MR imagingYguided high-intensity focused ultrasound (MR-HIFU) ablation, 69 specifically for the treatment of symptomatic uterine fibroids. By 2011, thousands of cases had been performed and scientific investigation was focused on the prediction of treatment outcome. Magnetic resonance offers many ways to assess tissue properties, with DCE-MR shown to be of utility for predicting ablation efficacy. Specifically, in a 2011 published study, 70 a high K trans at baseline was shown to be predictive of a poor treatment result, suggesting the use of higher acoustic power in such patients.
Because of the significance of this emerging field (interventional MR), the June 2013 issue of Investigative Radiology was dedicated to this subject. Interventional MR offers the advantages (compared with computed tomography [CT] and x-rayYbased approaches) of superior soft-tissue contrast, rapid multiplanar imaging, real-time guidance and monitoring, temperature mapping, and the absence of ionizing radiation (Fig. 4) . At the current time, therapy is being performed under MR guidance in clinical routine using cryoablation, 71 high-intensity focused ultrasound, 72,73 radiofrequency ablation, 74 and laser thermotherapy. 75, 76 This is a dynamic, evolving field, with some techniques well established for specific indications; in other areas, there are options with respect to treatment approach, with no therapy yet established as that of choice.
Tissue biopsy for the diagnosis of malignant disease is, today, also routinely performed under MR guidance, 77 with many indications, in particular for the breast and prostate.
FIGURE 4.
A small cholangiocellular carcinoma metastasis (arrow) to the liver is illustrated before treatment on enhanced T1-weighted (A) and after MR-guided radiofrequency ablation on enhanced T1-weighted (B), unenhanced T1-weighted (C), and T2-weighted (D) images. For tumor ablation, MR offers advantages over both CT and ultrasound because of higher lesion sensitivity, the ability to actively monitor the ablation with multiple sequences and in 3 dimensions, and the ability to measure tissue temperature (during the procedure). For identification of the ablated region, immediate posttreatment contrast enhanced T1-weighted scans serve as the accepted standard. Adapted from Rempp et al.
An additional area of research is that of improving visualization of surgical implants on MR. 78 In the short time span from 2010 to 2013, this area of investigation has proceeded from concept to animal evaluation 79 to assessment in humans. 80 Magnetic resonance offers, for the first time, a realistic approach to the evaluation of implants after surgery because of the high soft tissue contrast of the modality and the lack of ionizing radiation. Particularly in the initial area investigated, that of surgery for inguinal hernias, MR may prove invaluable for postsurgical assessment and evaluation of potential complications therein, including deformation, shrinkage, migration, or adhesions. This likely represents simply one application of many in the future, for the postoperative assessment of therapeutic success, with the eventual widespread development and use of easily MRvisualized surgical material.
MR-PET
For those who saw the development of CT, then MR, and then subsequently PET-CT, the advent of MR-PET is significant and presages a major new diagnostic modality. MR-PET required 2 important, nontrivial, technologic advances: (1) the ability to do wholebody MR imaging with high spatial resolution and (2) integration of PET detectors in the MR environment. Acquiring MR images during FIGURE 5. Bony metastases from a pheochromocytoma are visualized on scans obtained using an integrated whole-body 3-T MR-PET system, with 18 F-fluorodeoxyglucose used as the radiotracer. Illustrated are a coronal T1-weighted scan (A), maximum intensity projections of the PET data set in the coronal (B) and sagittal (C) views as well as fused MR-PET views in the coronal (D), sagittal (E), and axial (F) planes. Multiple tracer-avid bony lesions are identified, particularly in the spine, ribs, and pelvis. Adapted from Quick et al. During this time frame, it also became evident that whole-body DWI would play an important role in tumor evaluation, setting the stage for whole-body screening by MR with PET to include T1-, T2-, and diffusion-weighted scans. 81 It was soon shown that DWI, specifically with calculation of ADCs, held value as well for the assessment of treatment response in whole-body tumor MR imaging. 82 It may well be the case that MR-PET eclipses PET-CT in time, in clinical practice, because of the value of available additional parameters, DWI in particular, and because of image acquisition (MR and PET) being truly synchronous. 83 MR-PET combines the high sensitivity of PET with that of contrast-enhanced MR and its intrinsic high spatial resolution. The development of MR-PET has been technically challenging, and we will likely see very rapid evolution of this technology in the next 5 to 10 years. However, such hybrid systems, in which the acquisition of MR and PET images is truly synchronous, 84 have major diagnostic advantages over PET-CT in instances where MR outperforms CT (because of improved soft tissue contrast and reduced radiation dose). Hybrid MR-PET is feasible today with early clinical units, with detection rates similar to PET-CT, with attenuation correction performed at this time using Dixon sequences. 85 The clinical potential of MR-PET is clear in oncology (Fig. 5) , neurology, and cardiology, 86 with major additional potential advantages in special patient populations, for example, pediatrics, breast carcinoma, and prostate carcinoma. It should be kept in mind, however, that MR-PET is still very early in its development, with imaging approaches 87 and coil technology 88 still in rapid evolution. Early investigation in MR-PET for imaging of the prostate shows great promise, combining the high resolution of MR with molecular imaging, leading to increased diagnostic confidence in identifying and localizing prostate carcinoma. 89 An initial small patient series, comparing MR-PET and PET-CT, using 68-gallium-DOTA-D-Phe1-Tyr-octreotide in patients with known gastroenteropancreatic neuroendocrine tumors showed improved sensitivity for MR in identifying patients with malignant lesions, with known weaknesses inherent to MR, including specifically lung metastases and sclerotic bone lesions. 90 However, early investigation of areas considered as pitfalls for MR-PET, such as pulmonary nodules, shows success in overcoming potential problems and, thus, its integration into whole-body imaging. 91 In an additional larger patient series with 68-gallium-DOTA-D-Phe1-Tyr-octreotide, anatomic correlates for focal PET lesions could more often be delineated on MR than on low-dose CT, with coregistration of data superior on MR-PET as well. 92 Because of the significance of this emerging modality, the May 2013 issue of Investigative Radiology was dedicated to this subject.
CONCLUSIONS
As a major field within diagnostic radiology, MR continues to make rapid technological progress. Critical advances made in the past 5 years have major impact for current clinical diagnosis and portend as well future important developments. The domination of this topic, with more than 60% of published manuscripts in Investigative Radiology during 2009 to 2013 involving MR, reflects a vibrant research field. Continuing important developments in hardware and software are evident in many areas, with specific focus areas including the gradient systems, radiofrequency transmitter, and innovative pulse sequences, in particular the implementation of compressed sensing.
